Table 1. Baseline characteristics of included population based on the developmental dataset.
| Variable | PANDA III trial | |||
| Total (n = 1,263) | Non-POCE (n = 1,114) | POCE (n = 149) | P-value | |
| Values are presented as the mean ± SD or n (%). ACEF: age, creatinine and ejection fraction; CHD: coronary heart disease; LVEF: left ventricular ejection fraction; NSTEMI, non-ST-segment elevation myocardial infarction; QFR: quantitative flow ratio; STEMI: ST-segment elevation myocardial infarction; SYNTAX: Synergy Between Percutaneous Coronary Intervention with Taxus and Cardiac Surgery; PCI: percutaneous coronary intervention; POCE: patient-oriented composite endpoint. | ||||
| Age, yrs | 60.61 ± 10.59 | 60.19 ± 10.55 | 63.72 ± 10.40 | < 0.001 |
| Male | 897 (71.0%) | 783 (70.3%) | 114 (76.5%) | 0.140 |
| Body mass index, kg/m2 | 25.10 ± 3.35 | 25.19 ± 3.38 | 24.48 ± 3.12 | 0.016 |
| Hypertension | 791 (62.6%) | 687 (61.7%) | 104 (69.8%) | 0.066 |
| Diabetes | 294 (23.3%) | 251 (22.5%) | 43 (28.9%) | 0.107 |
| Insulin used | 84 (6.7%) | 72 (6.5%) | 12 (8.1%) | 0.578 |
| Hyperlipidemia | 417 (33.0%) | 364 (32.7%) | 53 (35.6%) | 0.540 |
| Smoking history | 639 (50.6%) | 557 (50.0%) | 82 (55.0%) | 0.286 |
| Family history of CHD | 77 (6.1%) | 70 (6.3%) | 7 (4.7%) | 0.564 |
| Peripheral vascular disease | 39 (3.1%) | 32 (2.9%) | 7 (4.7%) | 0.338 |
| Previous myocardial infarction | 228 (18.1%) | 195 (17.5%) | 33 (22.1%) | 0.204 |
| Previous PCI | 143 (11.3%) | 129 (11.6%) | 14 (9.4%) | 0.514 |
| Previous stroke | 143 (11.3%) | 114 (10.2%) | 29 (19.5%) | 0.001 |
| Creatinine, μmoI/L | 78.75 ± 45.83 | 78.01 ± 44.53 | 84.23 ± 54.48 | 0.012 |
| Creatinine Clearance, mL/min per 1.73m2 | 92.77 ± 50.43 | 93.92 ± 52.53 | 84.20 ± 29.21 | 0.027 |
| Left ventricular ejection fraction, % | 59.60 ± 8.66 | 59.69 ± 8.54 | 58.90 ± 9.52 | 0.025 |
| LVEF less than 40% | 36 (2.9%) | 31 (2.8%) | 5 (3.4%) | 0.895 |
| CHD type | ||||
| Asymptomatic ischemia | 41 (3.2%) | 36 (3.2%) | 5 (3.4%) | 0.246 |
| Stable angina | 199 (15.8%) | 180 (16.2%) | 19 (12.8%) | |
| Unstable angina | 653 (51.7%) | 583 (52.3%) | 70 (47.0%) | |
| NSTEMI | 181 (14.3%) | 156 (14.0%) | 25 (16.8%) | |
| STEMI | 189 (15.0%) | 159 (14.3%) | 30 (20.1%) | |
| Clinical presentation | ||||
| Acute coronary syndrome | 1023 (81.0%) | 898 (80.6%) | 125 (83.9%) | 0.396 |
| Acute myocardial infarction | 370 (29.3%) | 315 (28.3%) | 55 (36.9%) | 0.038 |
| Lesion vessel amount | ||||
| 1-vessel disease | 969 (76.7%) | 857 (76.9%) | 112 (75.2%) | 0.937 |
| 2-vessel disease | 267 (21.1%) | 233 (20.9%) | 34 (22.8%) | |
| 3-vessel disease | 27 (2.1%) | 23 (2.1%) | 4 (2.7%) | |
| Physiological Index | ||||
| Average baseline QFR | 0.61 ± 0.17 | 0.61 ± 0.17 | 0.55 ± 0.18 | < 0.001 |
| Average post-PCI QFR | 0.95 ± 0.08 | 0.96 ± 0.08 | 0.92 ± 0.11 | < 0.001 |
| Lowest post-PCI QFR | 0.94 ± 0.09 | 0.95 ± 0.09 | 0.91 ± 0.13 | < 0.001 |
| Post-PCI QFR ≤ 0.92 | 273 (21.6%) | 212 (19.0%) | 61 (40.9%) | < 0.001 |
| Classic clinical & angiographic risk scores | ||||
| ACEF Score | 1.05 ± 0.31 | 1.04 ± 0.29 | 1.15 ± 0.41 | < 0.001 |
| Modified ACEF Score | 1.30 ± 0.88 | 1.28 ± 0.83 | 1.50 ± 1.21 | 0.003 |
| Residual SYNTAX Score | 5.01 ± 6.00 | 4.96 ± 6.08 | 5.41 ± 5.37 | 0.038 |